Atrial fibrillation (AF) is a cardiac condition characterized by an irregular heart rhythm, which
is increasingly prevalent in the modern era. All international guidelines strongly advise the …

Background: Studies of acute venous thromboembolism (VTE) and non-valvular atrial
fibrillation (AF) have shown comparable therapeutic efficacy and similar or lower bleeding …

Abstract Purpose Factor Xa Inhibitors have emerged as a first-line agent in the management
of non-valvular atrial fibrillation (NVAF), but there is a need for additional data surrounding …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …

Background: Due to limited enrollment in landmark trials of patients with a BMI> 30 or
weight> 100 kg for apixaban and rivaroxaban, the International Society of Thrombosis and …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Background Atrial fibrillation and heart failure are combined risk factors for thromboembolic
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …

Background: Limited real-world data exist on the comparative effectiveness and safety of
direct oral anticoagulants (DOACs) compared to warfarin in obese patients with atrial …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …